| Literature DB >> 33017575 |
Zhijie Xu1, Bi Peng2, Yuan Cai2, Geting Wu2, Jinzhou Huang3, Ming Gao3, Guijie Guo3, Shuangshuang Zeng4, Zhicheng Gong4, Yuanliang Yan5.
Abstract
Several strategies, including chemotherapy and radiotherapy, have improved therapeutic outcomes among cancer patients in clinical practice. However, due to their heterogeneity, cancer cells frequently display primary or acquired therapeutic resistance, thereby resulting in treatment failure. The mechanisms underlying cancer therapeutic resistance are complex and varied. Among them, N6-methyladenosine (m6A) RNA modification has gained increasing attention as a potential determinant of therapy resistance within various cancers. In this review, we primarily describe evidence for the effect of the m6A epitranscriptome on RNA homeostasis modulation, which has been shown to alter multiple cellular pathways in cancer research and treatment. Additionally, we discuss the profiles and biological implications of m6A RNA methylation, which is undergoing intensive investigation for its effect on the control of therapeutic resistance.Entities:
Keywords: Chemoresistance; Immunotherapy resistance; N6-methyladenosine; Radioresistance; Targeted therapy resistance
Mesh：
Substances：
Year: 2020 PMID： 33017575 DOI： 10.1016/j.bcp.2020.114258
Source DB: PubMed Journal: Biochem Pharmacol ISSN： 0006-2952 Impact factor: 5.858